Diurnal leptin secretion is intact in male hypogonadotropic hypogonadism and is not influenced by exogenous gonadotropins. 2002

Guldem Kilciler, and Metin Ozata, and Cagatay Oktenli, and S Yavuz Sanisoglu, and Erol Bolu, and Necati Bingol, and Mete Kilciler, and I Caglayan Ozdemir, and Mustafa Kutlu
Department of Endocrinology and Metabolism, Gulhane School of Medicine, TR 06018 Etlik-Ankara, Turkey 06018.

Circulating leptin shows a pulsatile secretory pattern along with a nocturnal rise. We have previously shown that circulating leptin concentrations are high in males with untreated idiopathic hypogonadotropic hypogonadism (IHH). However, circadian leptin secretion in IHH before and after gonadotropin treatment is not known. Thus, we studied 14 adult males with IHH who had no history of previous hormonal therapy, and 12 age- and body mass index-matched healthy men. Plasma leptin concentrations were measured with 1-h intervals for 24 h before and 6 months after gonadotropin treatment. The 24-h mean leptin concentration showed a significant decrease, from 11.78 +/- 1.908 microg/liter at baseline to 10.85 +/- 1.939 microg/liter after 6 months of therapy (z = 3.107; P = 0.002). Before and after treatment, 24-h mean leptin concentrations were also significantly higher in the patient group when compared with controls (4.275 +/- 0.711 microg/liter) (z = 5.938; P = 0.0001). Hourly leptin levels demonstrated a diurnal pattern in hypogonadal patients, a surge in the midday, and a peak just after midnight, and this pattern did not differ before and after treatment. We observed a similar diurnal pattern in the control subjects too. Leptin levels were negatively and significantly correlated with free testosterone and total testosterone levels both before (r = -0.656, P = 0.011; and r = -0.639, P = 0.014, respectively) and after (r = -0.537, P = 0.048; and r = -0.563, P = 0.036, respectively) gonadotropin administration. Our observations suggest that the diurnal rhythm of leptin is intact in males with IHH, and short-term gonadotropin treatment does not effect its diurnal rhythm. Moreover, testosterone produced under the influence of the gonadotropin treatment led to decreases in the leptin levels.

UI MeSH Term Description Entries
D007006 Hypogonadism Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism). Hypergonadotropic Hypogonadism,Hypogonadism, Isolated Hypogonadotropic,Hypogonadotropic Hypogonadism,Hypogonadism, Hypergonadotropic,Hypogonadism, Hypogonadotropic
D008297 Male Males
D008596 Menotropins Extracts of urine from menopausal women that contain high concentrations of pituitary gonadotropins, FOLLICLE STIMULATING HORMONE and LUTEINIZING HORMONE. Menotropins are used to treat infertility. The FSH:LH ratio and degree of purity vary in different preparations. Gonadotropins, Human Menopausal,Human Menopausal Gonadotropin,CP-89044,CP-90033,HMG Ferring,HMG Lepori,HMG Massone,Humegon,Menogon,Menopur,Menotrophin,Normegon,ORG-31338,Pergonal,Pergonal-500,CP 89044,CP 90033,CP89044,CP90033,Gonadotropin, Human Menopausal,Human Menopausal Gonadotropins,Lepori, HMG,Menopausal Gonadotropin, Human,ORG 31338,ORG31338,Pergonal 500,Pergonal500
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D006062 Gonadotropins Hormones that stimulate gonadal functions such as GAMETOGENESIS and sex steroid hormone production in the OVARY and the TESTIS. Major gonadotropins are glycoproteins produced primarily by the adenohypophysis (GONADOTROPINS, PITUITARY) and the placenta (CHORIONIC GONADOTROPIN). In some species, pituitary PROLACTIN and PLACENTAL LACTOGEN exert some luteotropic activities. Gonadotropin
D006063 Chorionic Gonadotropin A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN). Chorionic Gonadotropin, Human,HCG (Human Chorionic Gonadotropin),Biogonadil,Choriogonadotropin,Choriogonin,Chorulon,Gonabion,Human Chorionic Gonadotropin,Pregnyl,Gonadotropin, Chorionic,Gonadotropin, Human Chorionic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013739 Testosterone A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL. 17-beta-Hydroxy-4-Androsten-3-one,17-beta-Hydroxy-8 alpha-4-Androsten-3-one,8-Isotestosterone,AndroGel,Androderm,Andropatch,Androtop,Histerone,Sterotate,Sustanon,Testim,Testoderm,Testolin,Testopel,Testosterone Sulfate,17 beta Hydroxy 4 Androsten 3 one,17 beta Hydroxy 8 alpha 4 Androsten 3 one,8 Isotestosterone
D020249 Hormone Replacement Therapy Therapeutic use of hormones to alleviate the effects of hormone deficiency. Replacement Therapy, Hormone,Therapy, Hormone Replacement,Hormone Replacement Therapies,Replacement Therapies, Hormone,Therapies, Hormone Replacement

Related Publications

Guldem Kilciler, and Metin Ozata, and Cagatay Oktenli, and S Yavuz Sanisoglu, and Erol Bolu, and Necati Bingol, and Mete Kilciler, and I Caglayan Ozdemir, and Mustafa Kutlu
May 1977, Fertility and sterility,
Guldem Kilciler, and Metin Ozata, and Cagatay Oktenli, and S Yavuz Sanisoglu, and Erol Bolu, and Necati Bingol, and Mete Kilciler, and I Caglayan Ozdemir, and Mustafa Kutlu
March 1993, Endocrinology and metabolism clinics of North America,
Guldem Kilciler, and Metin Ozata, and Cagatay Oktenli, and S Yavuz Sanisoglu, and Erol Bolu, and Necati Bingol, and Mete Kilciler, and I Caglayan Ozdemir, and Mustafa Kutlu
February 2023, MMW Fortschritte der Medizin,
Guldem Kilciler, and Metin Ozata, and Cagatay Oktenli, and S Yavuz Sanisoglu, and Erol Bolu, and Necati Bingol, and Mete Kilciler, and I Caglayan Ozdemir, and Mustafa Kutlu
January 1984, Endocrinologie,
Guldem Kilciler, and Metin Ozata, and Cagatay Oktenli, and S Yavuz Sanisoglu, and Erol Bolu, and Necati Bingol, and Mete Kilciler, and I Caglayan Ozdemir, and Mustafa Kutlu
July 1986, The Journal of the Association of Physicians of India,
Guldem Kilciler, and Metin Ozata, and Cagatay Oktenli, and S Yavuz Sanisoglu, and Erol Bolu, and Necati Bingol, and Mete Kilciler, and I Caglayan Ozdemir, and Mustafa Kutlu
September 1985, The New England journal of medicine,
Guldem Kilciler, and Metin Ozata, and Cagatay Oktenli, and S Yavuz Sanisoglu, and Erol Bolu, and Necati Bingol, and Mete Kilciler, and I Caglayan Ozdemir, and Mustafa Kutlu
January 2006, Journal of andrology,
Guldem Kilciler, and Metin Ozata, and Cagatay Oktenli, and S Yavuz Sanisoglu, and Erol Bolu, and Necati Bingol, and Mete Kilciler, and I Caglayan Ozdemir, and Mustafa Kutlu
May 2010, Molecular plant,
Guldem Kilciler, and Metin Ozata, and Cagatay Oktenli, and S Yavuz Sanisoglu, and Erol Bolu, and Necati Bingol, and Mete Kilciler, and I Caglayan Ozdemir, and Mustafa Kutlu
October 2012, Pediatric endocrinology reviews : PER,
Guldem Kilciler, and Metin Ozata, and Cagatay Oktenli, and S Yavuz Sanisoglu, and Erol Bolu, and Necati Bingol, and Mete Kilciler, and I Caglayan Ozdemir, and Mustafa Kutlu
January 1990, Minerva endocrinologica,
Copied contents to your clipboard!